-
Posted: September 1st, 2010, 8:00am CDT
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden...
-
Posted: September 1st, 2010, 2:00am CDT
Research conducted in the Netherlands has highlighted the need for care when switching patients under treatment for high cholesterol from branded to generic drug families. The study shows that much of the switching can result in patients inadvertently receiving non-equivalent doses, potentially leading to an increased risk of downstream heart disease and stroke...
-
Posted: August 27th, 2010, 3:00am CDT
Naringenin, an antioxidant derived from the bitter flavor of grapefruits and other citrus fruits, may cause the liver to break down fat while increasing insulin sensitivity, a process that naturally occurs during long periods of fasting...
-
Posted: August 26th, 2010, 5:00am CDT
Atherotech Diagnostics Lab will exhibit its VAP® Cholesterol Test in booth 105 at the National Lipid Association (NLA) Summer 2010 Clinical Lipid Update. The meeting takes place August 27-29 at the Mayflower Hotel in Washington, D.C...
-
Posted: August 23rd, 2010, 5:00am CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 mg/80 mg. Impax filed its Abbreviated New Drug Application ("ANDA") containing a paragraph IV certification for a generic version of VYTORIN® with the U.S. Food & Drug Administration ("FDA")...
-
Posted: August 13th, 2010, 4:00am CDT
Imagine this: order a cheeseburger and fries, and pick up a free cholesterol-busting statin tablet along with the other free condiments, that's what a group of UK researchers suggests you should be able to do at fast food outlets as a way to offset the increase in heart attack risk from eating junk food...
-
Posted: August 11th, 2010, 4:00am CDT
Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial...
-
Posted: August 6th, 2010, 5:00am CDT
Abbott has received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin - the most commonly prescribed dose of simvastatin - with either 500 mg or 1,000 mg of niacin extended-release...
-
Posted: August 5th, 2010, 10:00am CDT
From studies on mice, researchers in the US have discovered that disrupting the body clock or circadian rhythm could interfere with a normal 24 hour cycle of high and low triglycerides in a way that leaves them at a high level all the time, potentially raising the risk of atherosclerosis and heart disease. You can read how Dr M...
-
Posted: August 5th, 2010, 6:00am CDT
A global team of researchers co-led by the University of Michigan School of Public Health has discovered or confirmed 95 regions of the human genome where genetic variants are associated with blood cholesterol and triglyceride levels, which are major indicators of heart disease risk...
-
Posted: August 5th, 2010, 4:00am CDT
Two international studies published in a leading journal this week have pinpointed genes for cholesterol and heart disease that could be important targets for treatment, and demonstrate the potential clinical value of "genome scanning" or GWAS, genome wide association studies, in developing new diagnostic tests and therapies for diseases with genetic risks...
-
Posted: August 3rd, 2010, 12:00pm CDT
Researchers from of the Center for Obesity Research and Education at Temple University, Philadelphia have revealed that after a two-year comparison, a low-carb diet fares about as well as a low-fat diet with regards to weight loss, but low-carb improves cardiovascular risk factors more...
-
Posted: August 3rd, 2010, 11:00am CDT
Relatively young individuals with slightly abnormal cholesterol levels have a real risk of developing signs of heart disease by the time they are 45 years old, according to a new study published in the peer-reviewed medical journal Annals of Internal Medicine. In a 20-year study, researchers gathered data on 3,258 males and females between the ages of 18 and 30 years...
-
Posted: August 3rd, 2010, 5:00am CDT
Young people with even modestly elevated cholesterol levels are more likely to develop coronary artery calcium and atherosclerosis later in life, according to a 20-year study released on August 2 by UCSF researchers...
-
Posted: August 3rd, 2010, 5:00am CDT
At Two Years, Low-carb Diet Beats Low-Fat for HDL-Cholesterol Levels Previous studies comparing low-carbohydrate and low-fat diets have not included comprehensive behavioral treatment. Researchers sought to evaluate the long-term effects of a low-carbohydrate versus a low-fat diet when combined with a comprehensive lifestyle modification program...
-
Posted: August 3rd, 2010, 4:00am CDT
A new UCLA study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status...
-
Posted: July 29th, 2010, 6:00am CDT
Abbott received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin - the most commonly prescribed dose of simvastatin - with either 500 mg or 1,000 mg of niacin extended-release...
-
Posted: July 29th, 2010, 4:00am CDT
Abbott (NYSE: ABT) received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin the most commonly prescribed dose of simvastatin with either 500 mg or 1,000 mg of niacin extended-release...
-
Posted: July 27th, 2010, 3:00am CDT
Max Planck researchers explain the cause of the flushing effect arising from cholesterol treatment with nicotinic acid. Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma...
-
Posted: July 25th, 2010, 3:00am CDT
No firm conclusions about HDL cholesterol can be drawn from JUPITER sub-analysis Sophia Antipolis, 23 July 2010: The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet (1), could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol...
-
Posted: July 23rd, 2010, 4:00am CDT
Results of an international trial suggest that once statins have lowered LDL or "bad" cholesterol, the level of HDL or "good" cholesterol is less important in terms of predicting cardiovascular risk than it is during pre-treatment assessment...
-
Posted: July 22nd, 2010, 4:00am CDT
Most people know that high cholesterol levels place them at increased risk for heart disease and stroke. Prior research has shown that particular types of strokes contribute to one's risk for depression, and that abnormal blood lipid levels can increase the risk of depression in the elderly...
-
Posted: July 20th, 2010, 4:00am CDT
American Academy of Family Physicians - Coca-Cola Alliance, Conflict of Interest or Ethical Relationship? In an essay addressing the recent controversy over the American Academy of Family Physicians accepting a large corporate donation from The Coca-Cola Company to fund patient education materials on obesity prevention, family physician and AAFP member Howard Brody, M.D., Ph.D...
-
Posted: July 15th, 2010, 6:00am CDT
Recordati announces the positive outcome of the Decentralized Procedure for the approval of pitavastatin (Livazo®, Alipza® and other brands) in Europe following the communication from the Reference Member State (MHRA, Medicines and Healthcare products Regulatory Agency, UK) and the agreement of all the Concerned Member States which was received by Kowa...
-
Posted: July 14th, 2010, 4:00am CDT
Pfizer Inc...
-
Posted: July 14th, 2010, 3:00am CDT
The National Cholesterol Education Program maintains guidelines to assess the accuracy of methods for measuring cholesterol levels in patients. A recent study published in the journal Clinical Chemistry found that seven leading commercial methods produce results of mixed accuracy when compared to well-established techniques...
-
Posted: July 13th, 2010, 3:00am CDT
Relying on family history alone to decide which children should be screened for high cholesterol could miss many children who need treatment, according to the study, "Universal Versus Targeted Blood Cholesterol Screening Among Youth: The CARDIAC Project," published in the August print issue of Pediatrics (published online July 12)...
-
Posted: July 13th, 2010, 2:00am CDT
The analysis of the UK patient population from the DYSlipidaemia International Study (DYSIS UK), sponsored by MSD, found that 77.0% of the 383 statin-treated patients at high-risk from cardiovascular disease (CVD) who were studied achieved the JBS 2 guidelines' minimum standard of care*.(1) However, the study also found that 54...
-
Posted: July 8th, 2010, 6:00am CDT
Many of us are simply overloaded with cholesterol, and now a report in the July issue of Cell Metabolism brings what might be good news: There is more than one way to get rid of that cholesterol, which can otherwise lead to atherosclerosis and heart disease. "Cholesterol really can't be broken down," said Mark Brown of Wake Forest University School of Medicine...
-
Posted: July 1st, 2010, 7:00am CDT
Massachusetts General Hospital (MGH) investigators have found that an enzyme with several important roles in energy metabolism also helps to turn off the body's generation of fats and cholesterol under conditions of fasting...